What is Zacks Research’s Forecast for PAHC FY2025 Earnings?

Phibro Animal Health Co. (NASDAQ:PAHC) – Investment analysts at Zacks Research upped their FY2025 earnings per share estimates for shares of Phibro Animal Health in a research report issued to clients and investors on Tuesday, December 10th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $1.47 per share for the year, up from their prior forecast of $1.46. The consensus estimate for Phibro Animal Health’s current full-year earnings is $1.61 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q4 2025 earnings at $0.42 EPS, Q1 2026 earnings at $0.30 EPS, FY2026 earnings at $1.61 EPS, Q1 2027 earnings at $0.47 EPS and FY2027 earnings at $2.11 EPS.

Other equities analysts also recently issued reports about the stock. StockNews.com downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Friday, December 6th. Barclays increased their target price on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a research report on Tuesday, November 12th. JPMorgan Chase & Co. assumed coverage on Phibro Animal Health in a research note on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 price objective on the stock. Finally, Bank of America boosted their target price on Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research note on Friday, August 30th.

Phibro Animal Health Stock Down 0.3 %

Shares of NASDAQ:PAHC opened at $23.88 on Thursday. Phibro Animal Health has a 1 year low of $10.03 and a 1 year high of $25.98. The company has a market capitalization of $967.21 million, a PE ratio of 55.53, a price-to-earnings-growth ratio of 0.60 and a beta of 0.51. The business has a fifty day moving average price of $23.58 and a two-hundred day moving average price of $20.52. The company has a debt-to-equity ratio of 1.81, a current ratio of 3.23 and a quick ratio of 1.69.

Institutional Trading of Phibro Animal Health

Institutional investors and hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD boosted its stake in Phibro Animal Health by 7.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,393 shares of the company’s stock worth $200,000 after buying an additional 1,063 shares in the last quarter. CWM LLC raised its stake in Phibro Animal Health by 89.8% in the second quarter. CWM LLC now owns 2,188 shares of the company’s stock worth $37,000 after buying an additional 1,035 shares in the last quarter. Summit Securities Group LLC purchased a new position in shares of Phibro Animal Health in the 2nd quarter valued at approximately $83,000. Acadian Asset Management LLC lifted its position in Phibro Animal Health by 6.3% during the 2nd quarter. Acadian Asset Management LLC now owns 717,506 shares of the company’s stock valued at $12,027,000 after acquiring an additional 42,299 shares during the period. Finally, American Century Companies Inc. raised its stake in Phibro Animal Health by 119.6% during the second quarter. American Century Companies Inc. now owns 347,191 shares of the company’s stock valued at $5,822,000 after buying an additional 189,068 shares during the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 18th. Investors of record on Wednesday, November 27th will be issued a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a yield of 2.01%. The ex-dividend date is Wednesday, November 27th. Phibro Animal Health’s dividend payout ratio (DPR) is presently 111.63%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.